Tarsus Doses First Patient in Phase 2 Trial for Novel Oral Lyme Disease Preventative TP-05
TARS sits 74% above its 52-week low of $38.51.
Summary
Tarsus Pharmaceuticals has announced the dosing of the first participant in its Phase 2 Calliope clinical trial for TP-05, a novel investigational oral tablet designed for the potential prevention of Lyme disease. This marks a significant advancement in the company's pipeline, targeting a substantial unmet medical need as there are currently no FDA-approved pharmacological prophylactic options for Lyme disease. The trial aims to enroll approximately 700 healthy adults at risk for Lyme disease, with topline results expected in the first half of 2027. Successful development of TP-05 could establish Tarsus as a leader in a new prophylactic market, offering a unique on-demand oral solution. Investors should monitor the progress of this trial, with the next major catalyst being the release of Phase 2 topline data.
At the time of this announcement, TARS was trading at $66.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $38.51 to $85.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.